Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.
Identifieur interne : 002229 ( PubMed/Corpus ); précédent : 002228; suivant : 002230Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.
Auteurs : Maria Stamelou ; Alexander Reuss ; Ulrich Pilatus ; Jörg Magerkurth ; Petra Niklowitz ; Karla M. Eggert ; Andrea Krisp ; Thomas Menke ; Carmen Schade-Brittinger ; Wolfgang H. Oertel ; Günter U. HöglingerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- Adult, Aged, Basal Ganglia (drug effects), Basal Ganglia (metabolism), Double-Blind Method, Female, Humans, Magnetic Resonance Spectroscopy, Male, Middle Aged, Neuroprotective Agents (pharmacology), Neuroprotective Agents (therapeutic use), Supranuclear Palsy, Progressive (drug therapy), Ubiquinone (analogs & derivatives), Ubiquinone (pharmacology), Ubiquinone (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Ubiquinone.
- chemical , pharmacology : Neuroprotective Agents, Ubiquinone.
- drug effects : Basal Ganglia.
- drug therapy : Supranuclear Palsy, Progressive.
- metabolism : Basal Ganglia.
- chemical , therapeutic use : Neuroprotective Agents, Ubiquinone.
- Adult, Aged, Double-Blind Method, Female, Humans, Magnetic Resonance Spectroscopy, Male, Middle Aged.
Abstract
Mitochondrial complex I appears to be dysfunctional in progressive supranuclear palsy (PSP). Coenzyme Q(10) (CoQ(10)) is a physiological cofactor of complex I. Therefore, we evaluated the short-term effects of CoQ(10) in PSP. We performed a double-blind, randomized, placebo-controlled, phase II trial, including 21 clinically probable PSP patients (stage < or = III) to receive a liquid nanodispersion of CoQ(10) (5 mg/kg/day) or matching placebo. Over a 6-week period, we determined the change in CoQ(10) serum concentration, cerebral energy metabolites (by (31)P- and (1)H-magnetic resonance spectroscopy), motor and neuropsychological dysfunction (PSP rating scale, UPDRS III, Hoehn and Yahr stage, Frontal Assessment Battery, Mini Mental Status Examination, Montgomery Asberg Depression Scale). CoQ(10) was safe and well tolerated. In patients receiving CoQ(10) compared to placebo, the concentration of low-energy phosphates (adenosine-diphosphate, unphosphorylated creatine) decreased. Consequently, the ratio of high-energy phosphates to low-energy phosphates (adenosine-triphosphate to adenosine-diphosphate, phospho-creatine to unphosphorylated creatine) increased. These changes were significant in the occipital lobe and showed a consistent trend in the basal ganglia. Clinically, the PSP rating scale and the Frontal Assessment Battery improved slightly, but significantly, upon CoQ(10) treatment compared to placebo. Since CoQ(10) appears to improve cerebral energy metabolism in PSP, long-term treatment might have a disease-modifying, neuroprotective effect.
DOI: 10.1002/mds.22023
PubMed: 18464278
Links to Exploration step
pubmed:18464278Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.</title><author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name><affiliation><nlm:affiliation>Department of Neurology, Philipps University, Marburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Reuss, Alexander" sort="Reuss, Alexander" uniqKey="Reuss A" first="Alexander" last="Reuss">Alexander Reuss</name></author><author><name sortKey="Pilatus, Ulrich" sort="Pilatus, Ulrich" uniqKey="Pilatus U" first="Ulrich" last="Pilatus">Ulrich Pilatus</name></author><author><name sortKey="Magerkurth, Jorg" sort="Magerkurth, Jorg" uniqKey="Magerkurth J" first="Jörg" last="Magerkurth">Jörg Magerkurth</name></author><author><name sortKey="Niklowitz, Petra" sort="Niklowitz, Petra" uniqKey="Niklowitz P" first="Petra" last="Niklowitz">Petra Niklowitz</name></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M" last="Eggert">Karla M. Eggert</name></author><author><name sortKey="Krisp, Andrea" sort="Krisp, Andrea" uniqKey="Krisp A" first="Andrea" last="Krisp">Andrea Krisp</name></author><author><name sortKey="Menke, Thomas" sort="Menke, Thomas" uniqKey="Menke T" first="Thomas" last="Menke">Thomas Menke</name></author><author><name sortKey="Schade Brittinger, Carmen" sort="Schade Brittinger, Carmen" uniqKey="Schade Brittinger C" first="Carmen" last="Schade-Brittinger">Carmen Schade-Brittinger</name></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name></author><author><name sortKey="Hoglinger, Gunter U" sort="Hoglinger, Gunter U" uniqKey="Hoglinger G" first="Günter U" last="Höglinger">Günter U. Höglinger</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.22023</idno><idno type="RBID">pubmed:18464278</idno><idno type="pmid">18464278</idno><idno type="wicri:Area/PubMed/Corpus">002229</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.</title><author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name><affiliation><nlm:affiliation>Department of Neurology, Philipps University, Marburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Reuss, Alexander" sort="Reuss, Alexander" uniqKey="Reuss A" first="Alexander" last="Reuss">Alexander Reuss</name></author><author><name sortKey="Pilatus, Ulrich" sort="Pilatus, Ulrich" uniqKey="Pilatus U" first="Ulrich" last="Pilatus">Ulrich Pilatus</name></author><author><name sortKey="Magerkurth, Jorg" sort="Magerkurth, Jorg" uniqKey="Magerkurth J" first="Jörg" last="Magerkurth">Jörg Magerkurth</name></author><author><name sortKey="Niklowitz, Petra" sort="Niklowitz, Petra" uniqKey="Niklowitz P" first="Petra" last="Niklowitz">Petra Niklowitz</name></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M" last="Eggert">Karla M. Eggert</name></author><author><name sortKey="Krisp, Andrea" sort="Krisp, Andrea" uniqKey="Krisp A" first="Andrea" last="Krisp">Andrea Krisp</name></author><author><name sortKey="Menke, Thomas" sort="Menke, Thomas" uniqKey="Menke T" first="Thomas" last="Menke">Thomas Menke</name></author><author><name sortKey="Schade Brittinger, Carmen" sort="Schade Brittinger, Carmen" uniqKey="Schade Brittinger C" first="Carmen" last="Schade-Brittinger">Carmen Schade-Brittinger</name></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name></author><author><name sortKey="Hoglinger, Gunter U" sort="Hoglinger, Gunter U" uniqKey="Hoglinger G" first="Günter U" last="Höglinger">Günter U. Höglinger</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia (metabolism)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Spectroscopy</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (pharmacology)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (pharmacology)</term><term>Ubiquinone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Spectroscopy</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mitochondrial complex I appears to be dysfunctional in progressive supranuclear palsy (PSP). Coenzyme Q(10) (CoQ(10)) is a physiological cofactor of complex I. Therefore, we evaluated the short-term effects of CoQ(10) in PSP. We performed a double-blind, randomized, placebo-controlled, phase II trial, including 21 clinically probable PSP patients (stage < or = III) to receive a liquid nanodispersion of CoQ(10) (5 mg/kg/day) or matching placebo. Over a 6-week period, we determined the change in CoQ(10) serum concentration, cerebral energy metabolites (by (31)P- and (1)H-magnetic resonance spectroscopy), motor and neuropsychological dysfunction (PSP rating scale, UPDRS III, Hoehn and Yahr stage, Frontal Assessment Battery, Mini Mental Status Examination, Montgomery Asberg Depression Scale). CoQ(10) was safe and well tolerated. In patients receiving CoQ(10) compared to placebo, the concentration of low-energy phosphates (adenosine-diphosphate, unphosphorylated creatine) decreased. Consequently, the ratio of high-energy phosphates to low-energy phosphates (adenosine-triphosphate to adenosine-diphosphate, phospho-creatine to unphosphorylated creatine) increased. These changes were significant in the occipital lobe and showed a consistent trend in the basal ganglia. Clinically, the PSP rating scale and the Frontal Assessment Battery improved slightly, but significantly, upon CoQ(10) treatment compared to placebo. Since CoQ(10) appears to improve cerebral energy metabolism in PSP, long-term treatment might have a disease-modifying, neuroprotective effect.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18464278</PMID><DateCreated><Year>2008</Year><Month>06</Month><Day>03</Day></DateCreated><DateCompleted><Year>2008</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>942-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22023</ELocationID><Abstract><AbstractText>Mitochondrial complex I appears to be dysfunctional in progressive supranuclear palsy (PSP). Coenzyme Q(10) (CoQ(10)) is a physiological cofactor of complex I. Therefore, we evaluated the short-term effects of CoQ(10) in PSP. We performed a double-blind, randomized, placebo-controlled, phase II trial, including 21 clinically probable PSP patients (stage < or = III) to receive a liquid nanodispersion of CoQ(10) (5 mg/kg/day) or matching placebo. Over a 6-week period, we determined the change in CoQ(10) serum concentration, cerebral energy metabolites (by (31)P- and (1)H-magnetic resonance spectroscopy), motor and neuropsychological dysfunction (PSP rating scale, UPDRS III, Hoehn and Yahr stage, Frontal Assessment Battery, Mini Mental Status Examination, Montgomery Asberg Depression Scale). CoQ(10) was safe and well tolerated. In patients receiving CoQ(10) compared to placebo, the concentration of low-energy phosphates (adenosine-diphosphate, unphosphorylated creatine) decreased. Consequently, the ratio of high-energy phosphates to low-energy phosphates (adenosine-triphosphate to adenosine-diphosphate, phospho-creatine to unphosphorylated creatine) increased. These changes were significant in the occipital lobe and showed a consistent trend in the basal ganglia. Clinically, the PSP rating scale and the Frontal Assessment Battery improved slightly, but significantly, upon CoQ(10) treatment compared to placebo. Since CoQ(10) appears to improve cerebral energy metabolism in PSP, long-term treatment might have a disease-modifying, neuroprotective effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stamelou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Philipps University, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reuss</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pilatus</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Magerkurth</LastName><ForeName>Jörg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Niklowitz</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Eggert</LastName><ForeName>Karla M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Krisp</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Menke</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Schade-Brittinger</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Oertel</LastName><ForeName>Wolfgang H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Höglinger</LastName><ForeName>Günter U</ForeName><Initials>GU</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1339-63-5</RegistryNumber><NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EJ27X76M46</RegistryNumber><NameOfSubstance UI="C024989">coenzyme Q10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009682">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014451">Ubiquinone</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22023</ArticleId><ArticleId IdType="pubmed">18464278</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002229 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002229 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:18464278
|texte= Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18464278" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |